MGL-3196-11: A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to

Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation
https://www.clinicaltrials.gov/ct2/show/NCT03900429?term=MGL-3196&draw=4&rank=3
Age – Adult (18+)
Gender – Female, Male
Disease Type – Non-Alcoholic Steatohepatitis
Phase – 3
Length of Treatment – 4.5 years
Compensation available.

 

NN9931-4553 The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis

https://clinicaltrials.gov/ct2/show/NCT04822181

Age – Adult (18+)
Gender – Female, Male
Disease Type – Non-Alcoholic Steatohepatitis
Phase – 3a
Length of Treatment – 4.5 years
Compensation available.
 
 

Protocol #:VK2809-202 Protocol Title: VK2809 A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF VK2809 ADMINISTERED FOR 52 WEEKS FOLLOWED BY A 4-WEEK OFF-DRUG PHASE IN SUBJECTS WITH BIOPSY PROVEN NON-ALCOHOLIC STEATOHEPATITIS WITH FIBROSIS

https://clinicaltrials.gov/ct2/show/NCT04173065

Age – Adult (18+)
Gender – Female, Male
Disease Type – Non-Alcoholic Steatohepatitis
Phase – 2b
Length – 52 Weeks
Compensation available.